Adverse events possibly or probably related to the treatment regimen
| Patient* . | Grade 1 . | Grade 2 . |
|---|---|---|
| A | None | None |
| B | None | None |
| D | None | None |
| F | Chills, myalgias, and shortness of breath (all during IL-2 treatment) | Injection site skin reaction (during IL-2 treatment) |
| G | None | Injection site skin reaction (during IL-2 treatment) |
| H | Dysgeusia, fatigue, diaphoresis, and injection site skin reactions (all during IL-2 treatment) | Flulike syndrome (during IL-2 treatment) |
| I | Malaise/fatigue, chills, injection site reactions, and dyspnea (all during IL-2 treatment) | Fever (during IL-2 treatment) |
| Patient* . | Grade 1 . | Grade 2 . |
|---|---|---|
| A | None | None |
| B | None | None |
| D | None | None |
| F | Chills, myalgias, and shortness of breath (all during IL-2 treatment) | Injection site skin reaction (during IL-2 treatment) |
| G | None | Injection site skin reaction (during IL-2 treatment) |
| H | Dysgeusia, fatigue, diaphoresis, and injection site skin reactions (all during IL-2 treatment) | Flulike syndrome (during IL-2 treatment) |
| I | Malaise/fatigue, chills, injection site reactions, and dyspnea (all during IL-2 treatment) | Fever (during IL-2 treatment) |
None of the patients experienced any grade 3 or grade 4 events.
Patients C and E are omitted because they did not receive T-cell infusions.